TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16500015

Group type: EXPERIMENTAL
Intervention: ACLS intervention with early administration of sodium bicarbonate
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: ACLS intervention
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Transport time
Number of subjects: 874

Group type: COMPARATOR
Intervention: Bicarbonate administration
Number of subjects: 874
Study: 15631248

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study: 11884105

Group type: EXPERIMENTAL
Intervention: Enlargement reconstruction of the flexor retinaculum with synovectomy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional carpal tunnel release
Number of subjects: 91
Study: 9202101

Group type: EXPERIMENTAL
Intervention: Caffeine (240 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with supplemental caffeine (2 mg/kg body wt)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 10
Study: 7878506

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR) under general anesthesia (GA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Open hernia repair (OHR) under local anesthetic (LA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR)
Number of subjects: 86
Study: 3285017

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily via gastrointestinal tract for 21 days or until discharge)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 71
Study: 29047035

Group type: EXPERIMENTAL
Intervention: Super-Resolution Convolutional Neural Network (SRCNN)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Linear interpolation methods
Number of subjects: 89
Study: 28619176

Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25614603

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (CAF) 0.3 g/25 ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maltodextrin mouth rinse (MALT) 1.6 g/25 ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLAC)
Number of subjects: 10
Study: 22633472

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin (sim80)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin and 10 mg ezetimibe (sim10eze10)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 20680372

Group type: EXPERIMENTAL
Intervention: Surgical decompression of the lumbar spine without fusion
Number of subjects: 159
Study: 19463387

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté 2.25 mm
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté 38 mm
Number of subjects: 411

Group type: COMPARATOR
Intervention: TAXUS Express
Number of subjects: 411
Study: 17406757

Group type: EXPERIMENTAL
Intervention: H. pylori treatment with omeprazole, clarithromycin, and amoxicillin for 7 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: H. pylori positive rate in tumor tissue
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: H. pylori presence in adjacent non-tumor gastric mucosa
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Comparison of H. pylori prevalence in intestinal vs diffuse carcinomas
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chronic gastritis and atrophic mucosa in adjacent non-tumor gastric mucosa
Number of subjects: 56
Study: 12793516

Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study: 11053707

Group type: EXPERIMENTAL
Intervention: Short-term heart rate variability (HRV) analysis before ventricular tachycardia (VT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spectral analysis of HRV before VT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaling exponent beta of the power-frequency relation before VT
Number of subjects: 0
Study: 8971904

Group type: EXPERIMENTAL
Intervention: Gentamicin (9 infants, group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amikacin (10 infants, group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Netilmicin (10 infants, group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (10 newborns who did not receive antibiotics)
Number of subjects: 30
Study: 1281066

Group type: EXPERIMENTAL
Intervention: Flow cytometry with thiazole orange
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Flow cytometry with thiazole orange (increased concentration)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Flow cytometry, image analysis, manual counting
Number of subjects: 289
Study: 6089074

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) at 80 microseconds rectangular waves at 85 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation at 0.5 Hz
Number of subjects: 0
Study: 30739002

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in addition to best available care
Number of subjects: 520

Group type: COMPARATOR
Intervention: Best available care without NIV
Number of subjects: 520
Study: 29336914

Group type: EXPERIMENTAL
Intervention: Prasugrel 60mg loading dose (G3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel 30mg loading dose (G2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg loading dose (G1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clopidogrel (G4)
Number of subjects: 100
Study: 27630211

Group type: EXPERIMENTAL
Intervention: FABP4 levels measured in early pregnancy (median 14 weeks' gestation)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: FABP4 levels measured in the second trimester (median 26 weeks' gestation)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Elevated second-trimester FABP4 level
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Addition of FABP4 to established risk factors
Number of subjects: 710
Study: 24842870

Group type: EXPERIMENTAL
Intervention: 1 h nurse-led one-on-one teaching session about their heart
Number of subjects: 58
Study: 22952179

Group type: EXPERIMENTAL
Intervention: Dietary behavior modification (D)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Physical exercise behavior modification (E)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined dietary and physical exercise behavior modification (DE)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (usual care) (C)
Number of subjects: 68
Study: 19246029

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy skills training (DBT‐ST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard group therapy (SGT)
Number of subjects: 60
Study: 17259081

Group type: EXPERIMENTAL
Intervention: 200 mg suprofen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 400 mg suprofen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 11
Study: 15088181

Group type: EXPERIMENTAL
Intervention: 200 mg/ml iodine concentration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 250 mg/ml iodine concentration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 mg/ml iodine concentration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 350 mg/ml iodine concentration
Number of subjects: 100
Study: 11257152

Group type: EXPERIMENTAL
Intervention: Hyaluronan (Hyalgan) - 2 ml of 500-730 000 MW hyaluronan, 10 mg/ml in saline, one injection per week for 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (Depomedrol) - 1 ml of methylprednisolone acetate, 40 mg/ml, one injection per week for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments (Hyalgan and Depomedrol)
Number of subjects: 0
Study: 9732167

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 47
Study: 8059043

Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil-flumazenil
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 63

Group type: COMPARATOR
Intervention: Isoflurane-alfentanil
Number of subjects: 63
Study: 3391872

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid for 7-14 days
Number of subjects: 474

Group type: COMPARATOR
Intervention: Erythromycin base enterocoated pellets in capsules (EB enterocapsules) 500 mg tid for 7-14 days
Number of subjects: 474

Group type: COMPARATOR
Intervention: Erythromycin base enterocoated tablets (EB enterotablets) 500 mg tid for 7-14 days
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Erythromycin base enterocoated pellets in capsules (EB enterocapsules)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Erythromycin base enterocoated tablets (EB enterotablets)
Number of subjects: 474
Study: 31618071

Group type: EXPERIMENTAL
Intervention: Point-of-Care Clinical Trials (POC-CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of Electronic Medical Record (EMR) and Bayesian adaptive feature
Number of subjects: 0
Study: 30216846

Group type: EXPERIMENTAL
Intervention: Long-term PM2.5 exposure (1-year and 6-month average)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Long-term PM2.5 exposure (1-year average)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-199a/b
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: miR-223-3p
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PM2.5 ambient levels
Number of subjects: 22
Study: 27049103

Group type: EXPERIMENTAL
Intervention: Intranasal T-LysYal
Number of subjects: 83

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 83
Study: 24916336

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with adriamycin plus ifosfamide
Number of subjects: 140

Group type: COMPARATOR
Intervention: Perioperative chemotherapy with gemcitabine and docetaxel
Number of subjects: 140
Study: 21035211

Group type: EXPERIMENTAL
Intervention: Early abciximab administration
Number of subjects: 110

Group type: COMPARATOR
Intervention: Late abciximab administration
Number of subjects: 110
Study: 19830486

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque, GE Healthcare, United Kingdom) administered during endovascular procedure, average 99.3 ml (range 60-180 ml)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no contrast medium administered)
Number of subjects: 87
Study: 18093199

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonanimal-stabilized hyaluronic acid (NASHA)
Number of subjects: 60
Study: 16639342

Group type: EXPERIMENTAL
Intervention: d4T+ddI
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ddI
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ZDV
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 373
Study: 12745489

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 21
Study: 11095476

Group type: EXPERIMENTAL
Intervention: 50 microg ethinylestradiol (EE) for 7 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 50 microg ethinylestradiol (EE) for 2 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide followed by 50 mg captopril after 7 days of EE
Number of subjects: 2
Study: 8810655

Group type: EXPERIMENTAL
Intervention: Desmin 100 mg once daily SC
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Desmin 100 mg twice a day SC
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Desmin 200 mg once daily IM
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Desmin (all doses)
Number of subjects: 56
Study: 1350796

Group type: EXPERIMENTAL
Intervention: lisinopril (10‐20 mg once daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: hydrochlorothiazide (12.5‐25 mg once daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: beta-blocker + diuretic
Number of subjects: 38

Group type: COMPARATOR
Intervention: beta-blocker + ACE inhibitor
Number of subjects: 38
Study: 4083464

Group type: EXPERIMENTAL
Intervention: Nimodipine 1.0 micrograms/kg body weight per minute in addition to 0.1 mg fentanyl/patient
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia (mean: 2.45 mg fentanyl/patient)
Number of subjects: 20
Study: 31221297

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) supplementation (35 g daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study: 30462790

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 32
Study: 28202846

Group type: EXPERIMENTAL
Intervention: MFGM tablets (1 g MFGM/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 22
Study: 24670140

Group type: EXPERIMENTAL
Intervention: 1.2 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.3 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1) with 0.4 g.kg‐1.h‐1 whey protein hydrolysate
Number of subjects: 0
Study: 22812907

Group type: COMPARATOR
Intervention: hCG administration 35-36 h prior to oocyte retrieval (Group A)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: hCG administration delayed by 1 day (Group B)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: hCG administration delayed by 2 days (Group C)
Number of subjects: 125
Study: 20116841

Group type: EXPERIMENTAL
Intervention: 30 mg ulipristal acetate
Number of subjects: 2221

Group type: COMPARATOR
Intervention: 1.5 mg levonorgestrel
Number of subjects: 2221

Group type: EXPERIMENTAL
Intervention: Meta-analysis of ulipristal acetate
Number of subjects: 2221

Group type: COMPARATOR
Intervention: Meta-analysis of levonorgestrel
Number of subjects: 2221
Study: 17573494

Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT)
Number of subjects: 55
Study: 16640634

Group type: EXPERIMENTAL
Intervention: Harvard cement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fuji PLUS cement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Variolink II cement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative control group (gutta‐percha and sealer)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Positive control group (gutta‐percha only)
Number of subjects: 45
Study: 12919339

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eight drugs for primary generalized tonic-clonic seizures
Number of subjects: 0
Study: 10970716

Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings (males)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Few clinical signs of fatty acid deficiency
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings (females)
Number of subjects: 97
Study: 8973872

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1462990

Group type: EXPERIMENTAL
Intervention: ALG 15 mg/kg just before transplant surgery, ALG 12 mg/kg the first day after transplant, followed by four doses of 10 mg/kg on alternate days
Number of subjects: 140

Group type: COMPARATOR
Intervention: OKT3 5 mg just before transplant, followed by four doses of 5 mg/d
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ALG group
Number of subjects: 140

Group type: COMPARATOR
Intervention: OKT3 group
Number of subjects: 140
Study: 4028871

Group type: EXPERIMENTAL
Intervention: Lymecycline 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Doxycycline 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lymecycline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 8
Study: 31856495

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study: 30367243

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 28535959

Group type: EXPERIMENTAL
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine and 1mg/kg rectal‐diclofenac
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine and 30mg/kg rectal paracetamol
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine
Number of subjects: 90
Study: 25495835

Group type: EXPERIMENTAL
Intervention: Multimedia educational tools
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional 'study day' teaching
Number of subjects: 43
Study: 23443282

Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison between PEEP 15 cm H2O and PEEP 5 cm H2O
Number of subjects: 14
Study: 21659058

Group type: EXPERIMENTAL
Intervention: Oral magnesium (6x419 mg Mg chloride/capsule per day for a month)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 45
Study: 18450851

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-acellular pertussis immunization
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (no immunization)
Number of subjects: 191
Study: 16555167

Group type: EXPERIMENTAL
Intervention: Hypericum extract STW3-VI (900 mg)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 16279863

Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine combined with fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone added to ongoing therapy
Number of subjects: 0
Study: 10996349

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (1 or 2 tablets per day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (1 tablet per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9327191

Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Propiomazine 25 mg
Number of subjects: 135
Study: 1337553

Group type: EXPERIMENTAL
Intervention: Azithromycin, 10 mg/Kg/day per os once daily for 3 days or 10 mg/Kg/day on day 1 and 5 mg/Kg/day on days 2-5 (77 patients)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Erythromycin, 50 mg/Kg/day thrice daily for at least 7 days (74 patients)
Number of subjects: 151
Study: 3903732

Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 49781

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49781
Study: 30545923

Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lenalidomide + Azacitidine (75mg/m2/d days 1 to 5 with lenalidomide 10mg days 1‐21 of 28‐day cycle from cycle 3)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lenalidomide + Azacitidine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both arms (Azacitidine and Lenalidomide + Azacitidine)
Number of subjects: 160
Study: 30566442

Group type: EXPERIMENTAL
Intervention: Knowledge of ARV ADR defining criteria
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Knowledge of the system's purpose
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Knowledge of the reporting process
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Identification of ARV ADRs following client complaints
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Enquiry about clients' medication response
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cited non-feedback from MCAZ for underreporting
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Inadequate ARV ADR identification skills
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Availability of reporting forms
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Therapeutic decisions made from ARV ADRs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Usefulness score of the pharmacovigilance system
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Case detection rate
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Data quality
Number of subjects: 52
Study: 26719232

Group type: EXPERIMENTAL
Intervention: Standard of care plus docetaxel (SOC + Doc)
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Standard of care plus zoledronic acid (SOC + ZA)
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc)
Number of subjects: 2962

Group type: COMPARATOR
Intervention: Standard of care only (SOC-only)
Number of subjects: 2962
Study: 25230681

Group type: EXPERIMENTAL
Intervention: Dietary fibre intake
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Combination of low saturated fat intake and high cardiorespiratory fitness
Number of subjects: 1114
Study: 22768458

Group type: EXPERIMENTAL
Intervention: O packed cell (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: O dried packed cell (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: O packed cell (group 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Infant isogroup (group 4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Infants with two transfusions
Number of subjects: 100
Study: 20146649

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15